Angelini Pharma launches lurasidone hydrocloride-based Latuda in Spain for the treatment of shizophrenia

During the XXII Spanish National Congress of Psychiatry, held from 26 to 28 September in Bilbao, Angelini Pharma launched Latuda (lurasidone hydrochloride) in Spain for the treatment of schizophrenia, a pathology that affects around 450,000 people in Spain.

Latuda’s introduction to the Spanish market follows its launch in Italy, where the drug has been marketed by Angelini Pharma since 2017. On a global level, it has been prescribed for over 13 million patients since January 2011, when the drug was placed on the market by the Japanese company Sumitomo Dainippon Pharma Co. In less than a decade, it has become the world’s most prescribed branded antipsychotic.